Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin that is Lilly’s top selling drug, bringing in almost $700 ...

Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning ... at mealtimes for example – with fast-acting insulins. The cost of insulin products ...

Some diabetes patients this year have had trouble finding their preferred insulin brands as major drug manufacturers reported ... need steady access to short-acting insulin. Which insulin brands ...

If your fasting blood sugar is normal but your blood sugar is elevated after meals, then rapid-acting insulin would be more appropriate, Kagan says. Insulin can also be combined with oral diabetes ...

Wockhardt Limited, the global pharmaceutical company, has submitted its indigenously developed fast-acting insulin analog, ASPARAPID, for regulatory approval with India’s Drugs Controller ...

In 2023, US diabetes patients encountered difficulties accessing insulin as major drug manufacturers reported ... importance of steady access to short-acting insulin, which is essential for ...